| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Blocking antibody for T cell suppressive factors is an innovative melanoma therapy. In the previous study, we have identified 80 candidate molecules for novel T cell suppressive factors. Among them, we characterized some molecules that were useful as targets of melanoma therapy. We found that an inhibitory signal from CD155 on melanoma cells to TIGIT on T cells was selectively enhanced in the tumor environment. Also we have demonstrated that blocking antibody for TIGIT enhanced the anti-melanoma T cell response cooperatively with anti PD-1 antibody. Our data suggested the usefulness of anti-TIGIT blocking antibody as a novel melanoma therapy.
|
